✨ Free AI Report
Zoetis Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Zoetis Inc.
Company Research

Zoetis Inc.: Business Overview, Financials & Competitive Analysis

Zoetis Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Established market leader with solid 2026 guidance and pipeline momentum, but navigating OA product safety concerns and consumer spending pressures in companion animals. Zoetis demonstrates robust fundamentals with 6% organic revenue growth, strong 43.8% EBITDA margins, and commanding market leadership. However, recent regulatory scrutiny on monoclonal antibody products, macroeconomic pressure.

What is Zoetis Inc.'s industry? Zoetis Inc. (zoetis.com) operates in Animal Health / Veterinary Pharmaceuticals & Biologics. AskCyborg classifies Zoetis Inc. under Animal Health / Veterinary Pharmaceuticals & Biologics in its company registry.

Zoetis Inc. is the global leader in animal health, developing medicines, vaccines, diagnostics, and technologies for companion animals and livestock. With a diversified portfolio spanning 68% companion animals (dogs, ...

7/ 10Strong

Cyborg Score thesis

Established market leader with solid 2026 guidance and pipeline momentum, but navigating OA product safety concerns and consumer...

Read the full analyst-debate transcript →
Industry Animal Health / Veterinary Pharmaceuticals & Biologics
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Zoetis Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Zoetis Inc.

AskCyborg analysts argue the bull and bear cases for Zoetis Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Zoetis Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Zoetis Inc. Overview

Pro stress-test →

Zoetis Inc. is the global leader in animal health, developing medicines, vaccines, diagnostics, and technologies for companion animals and livestock. With a diversified portfolio spanning 68% companion animals (dogs, cats, horses) and 31% livestock (cattle, swine, poultry, fish, sheep), the company serves veterinarians, livestock producers, and pet owners worldwide.

Strategic Profile

Pro stress-test →

Zoetis employs a "Continuum of Care" strategy—Predict, Prevent, Detect, and Treat—to capture revenue across an animal's entire lifecycle through genetic testing, vaccines, diagnostics, and therapeutics. The company maintains a dominant market position fortified by strong R&D innovation, with a 12-candidate blockbuster pipeline targeting high-value therapeutic areas including chronic kidney disease and oncology.

Competitive Landscape

Pro stress-test →

Zoetis competes against IDEXX Laboratories in diagnostics and companion animal care, and Elanco Animal Health in livestock and parasiticides. The company differentiates through its comprehensive portfolio spanning species and channels, plus superior R&D pipeline depth. While Elanco faces pricing headwinds, Zoetis maintains premium positioning supported by 72% gross margins and innovation velocity.

Industry Context

Zoetis Inc. operates in Animal Health / Veterinary Pharmaceuticals & Biologics.

Key facts

Founded: 1950 · Headquarters: Parsippany, New Jersey, US · Revenue: $9.5B · Market cap: $56.8B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Zoetis Inc..

  • Companion animal segment driving 68% of revenue with humanization of pets supporting premium pricing for specialty care in dermatology, parasiticides, and pain management
  • 2025 full-year revenue of $9.5B with 6% organic growth demonstrates resilience despite regulatory headwinds on pain portfolio products (Librela, Solensia)
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Reported FY2025 results: $9.5B revenue (+6% organic), $1.48 Q4 EPS beat, 2026 guidance $7.00-$7.10 EPS ($9.83-$10.03B revenue)
  • January 2026EU approval of Portela (monoclonal antibody for cat osteoarthritis), first three-month OA treatment for felines
  • +2 moreTrack every material event for Zoetis Inc. as it happens. Explore monitoring →
Get alerted when Zoetis Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

IDEXX LaboratoriesDiagnostics leader in companion animal and livestock diagnostics→Elanco Animal HealthLivestock and parasiticide competitor facing pricing pressure→Merck Animal HealthDiversified animal health portfolio within larger pharma→Boehringer Ingelheim Animal HealthGlobal animal health division with vaccines and parasiticides→

Compare Zoetis Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Zoetis Inc. operates in Animal Health / Veterinary Pharmaceuticals & Biologics. See how the rest of the sector scores on the Cyborg framework.

Browse Animal Health / Veterinary Pharmaceuticals & Biologics research →
NEW · MCP server

Ask your AI assistant about Zoetis Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Zoetis Inc. and its top competitor on Cyborg Score”
“What did Zoetis Inc. do this quarter?”
“Is Zoetis Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Zoetis Inc. do?+
Zoetis Inc. is the global leader in animal health, developing medicines, vaccines, diagnostics, and technologies for companion animals and livestock. With a diversified portfolio spanning 68% companion animals (dogs, ...
What is Zoetis Inc.'s Cyborg Score?+
Zoetis Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Zoetis Inc.'s main competitors?+
Named competitors include IDEXX Laboratories, Elanco Animal Health, Merck Animal Health, Boehringer Ingelheim Animal Health. The full competitive landscape is in the AskCyborg report.
How can I get the full Zoetis Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Zoetis Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Zoetis Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Animal Health research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Sequent Scientific Limited7Vimian Group AB